课题基金 / 基金详情

Disruption of natural healing process in autoimmune myocarditis and progression to dilated cardiomyopathy

Disruption of natural healing process in autoimmune myocarditis and progression to dilated cardiomyopathy
自身免疫性心肌炎自然愈合过程的破坏和扩张型心肌病的进展
批准号:
12670653
负责人:
HANAWA Haruo
金额:
$2.05万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

HANAWA Haruo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
(1) Marker in myocarditisElevation of sFas and sFasL levels at initial presentation appear to be a good serological marker to predict the prognosis of acute myocarditis. MCP-1 may play an important role in the pathogenesis of human acute myocarditis as well as in the progression of rat Experimental autoimmune myocarditis (EAM). Serum IL-10 levels may play a role m evaluation of the disease activity in patients with cardiac sarcoidosis.(2) Therapy for myocarditisA low dose of carvedilol has beneficial effects on rat dilated cardiomyopathy The area of myocardial fibrosis in chronic phase of Experimental autoimmune myocarditis was markedly reduced by quinapril. Bisoprolol improved survival independently, of its effect on left ventricular function by reducing sudden death in EAM. The prevention of EAM by administering the anti-CD 2 monoclonal antibody resulted from T cell depletion during theinduction phase,(3) Gene therapy for EAMGene transfer into muscle by electroporation in vivo is an … More effective means of delivery of IL-10, INFγ receptor-IgG, secretary leukocyte protease inhibitor-IgG and CTLA4-IgG for the treatment of autoimmune myocarditis.(4) Time Course of Gene Expression in EAMα-cardiac myosin showed a 26-fold decrease and β-cardiac myosm a 3.9-fold increase at day 14. ANP and BNP increased 48- and 6.4-fold respectively at day 21 and 14. AT1 receptor, ACE and ET1 increased 22- at day 21, 6.3- at day 21 and 17-fold, respectively at day 14. Aldosterone receptor decreased 2.2-fold at day 14, but aldsterone synthethase was detected only at day 14 and 21. Interleukin (IL) -2, IL-10, interferon-γ and monocyte chemoattractant protein-1 increased 9.1- at day 14, 398- at day 21, 43- at day 14 and 142-fold at day 14, respectively. Collagen type 3, Collagen type 1 and fibronectin increased 35-, 1.7- and 45- fold at day 21. Interestingly, osteopontin showed a 4542-fold increase and it was the higtest mRNA of all at day 14.Isoform of cardiac myosin and NP are dramatically changed in EAM. RAA and ET expressions are changed diversely in EAM time course. Cytokine, chemokine and ECM greatly increase and, especially, large numbers of osteopontin mRNA are expressed in early EAM. Less
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Fuse, K.: "Enhanced expression and production of monocyte chemoattractant protein 1 in myocarditis"Clin Exp Immunol. 124. 346-352 (2001)
Fuse, K.:“心肌炎中单核细胞趋化蛋白 1 的表达和产生增强”Clin Exp Immunol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Watanabe, K.: "Acute effects of endotheiin-1 and TAK-044 (ET(A) and ET(B) receptor antagonist) in rats with dilated cardiomyopathy"J Cardiovasc Pharmacol. 36. S49-54 (2000)
Watanabe, K.:“内皮素-1 和 TAK-044(ET(A) 和 ET(B) 受体拮抗剂)对扩张型心肌病大鼠的急性作用”J Cardiovasc Pharmacol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Watanabe Kら: "Bisoprolol improves survival in rats with heart failure"J Cardiovasc Pharmacol. 38. S55-S58 (2001)
Watanabe K 等人:“比索洛尔改善心力衰竭大鼠的存活率”J Cardiovasc Pharmacol 38. S55-S58 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ohta, Y.: "Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart"J Cardiovasc Pharmacol. 36. S19-23 (2000)
Ohta, Y.:“卡维地洛增强大鼠心脏中心房和脑钠尿肽 mRNA 的表达和释放”J Cardiovasc Pharmacol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
25
    Inspection of receptor-Ig protein heterodimer for inhibition of its ligand
    • 批准号:
      20591185
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2008
    • 负责人:
      HANAWA Haruo
    • 依托单位:
    Gene expression in myocarditis and dilated cardiomyopathy and basic study of gene therapy by plasmid
    • 批准号:
      14570645
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2002
    • 负责人:
      HANAWA Haruo
    • 依托单位:
    海外基金